Updates are available Correction dated 2025-03-28
Click to view Correction: https://doi.org/10.1186/s13148-025-01848-6
-
Authors
Martino, David
Schultz, Nikki
Kaur, Ravinder
van Haren, Simon D.
Kresoje, Nina
Hoch, Annmarie
Diray-Arce, Joann
Su, Jessica Lasky
Levy, Ofer
Pichichero, Michael
,
-
Funding
Funding for this research was provided by:
National Institutes of Health (U19AI168643, U19AI168643, U19AI168643, U19AI168643, U19AI168643, U19AI168643, U19AI168643, U19AI168643, U19AI168643, U19AI168643)
- License Information
-
More Information
Article History
Received: 25 March 2024
Accepted: 30 June 2024
First Online: 3 July 2024
Change Date: 28 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13148-025-01848-6
Declarations
:
: The study ethics and protocol were approved by The Rochester Regional Health Human Subjects Review Board under the approval number CIC 1141-B-09-1.
: All authors have agreed to publish this manuscript on Clinical Epigenetics.
: JL-S is a scientific advisor to Precion Inc. and TruDiagnostic Inc. OL and SvH are named inventors on patents related to vaccine adjuvants and human in vitro systems that model immune responses. Their laboratories have received a sponsored research agreement from GlaxoSmithKline (GSK). OL is a co-founder of Ovax LLC.
